Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-64264681 in NHL and CLL
NCT04210219Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of JNJ-64264681 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity up to 21 days and Adverse Events up to 2 years. Started Jul 2020; status: completed.
02
Drugs
JNJ-64264681
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04210219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210219.